NCT05706454: Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia |
|
|
| Recruiting | 2/3 | 324 | RoW | Ramatroban, BAYu3405, IUPAC Name: 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid, Placebo | KARE Biosciences, JSS Medical Research Inc., Biomedical Advanced Research and Development Authority, Open Philanthropy, Charak Laboratories India Pvt. Ltd, Charak Foundation, BioLink Life Sciences, Inc. | COVID-19 Pneumonia, COVID-19 Respiratory Infection | 07/24 | 05/26 | | |
